Las Vegas, NV -- (SBWIRE) -- 10/07/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: Buka Ventures Inc(OTCBB:NNRX), Applied DNA Sciences Inc(OTCMKTS:APDN), Elite Pharmaceuticals Inc(OTCBB:ELTP), Advanced Cell Technology, Inc.(OTCMKTS:ACTC)
Buka Ventures Inc(OTCBB:NNRX) was trading higher by 0.020 points or +5.26% to $0.400.So far, around 576,013.00 shares have changed hands in this session. After opening at $0.39, the stock hit as high as $0.42. However, it traded between $0.12and $1.48 over the last twelve months.
For How Long NNRX will Fight for Profitability? Read This Trend Analysis report
Applied DNA Sciences Inc(OTCMKTS:APDN) was at $0.0931, showing a -5.96% decrease. Around 2.64 million shares have been traded, versus an-average trading volume of 3.37M shares. The company is now valued at around $73.68 million. Applied DNA Sciences, Inc. provides botanical-DNA based security and authentication solutions in Europe and the United States.
Has APDN Found The Bottom And Ready To Gain Momentum? Find Out Here
Elite Pharmaceuticals Inc(OTCBB:ELTP) moved -4.81 per cent lower at $0.133 and is trading between $0.13 and $0.14 after opening the day at $0.14. Its performance over the last five days remained +10.58%, which stands at +10.58% for a month. Going back further than one month, 1-year performance after recent close was +10.58%. Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, principally engages in the research, development, and licensing of proprietary controlled-release drug delivery systems and products.
Why Should Investors Buy ELTP After the Recent Fall? Just Go Here and Find Out
Advanced Cell Technology, Inc.(OTCMKTS:ACTC)’s is at to $0.0711. The stock is up around 26.93% in 2013 and -0.42% for the last 12 months. Around 2.99 million shares changed hands so far in this sessioncompared to an-average trading volume of 7.89M shares. Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine.
What ACTC’s Charts Are Signaling for Traders? Find Out Here
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)